[go: up one dir, main page]

PL3759096T3 - Inhibitory cd73 - Google Patents

Inhibitory cd73

Info

Publication number
PL3759096T3
PL3759096T3 PL19709335T PL19709335T PL3759096T3 PL 3759096 T3 PL3759096 T3 PL 3759096T3 PL 19709335 T PL19709335 T PL 19709335T PL 19709335 T PL19709335 T PL 19709335T PL 3759096 T3 PL3759096 T3 PL 3759096T3
Authority
PL
Poland
Prior art keywords
inhibitors
Prior art date
Application number
PL19709335T
Other languages
English (en)
Inventor
Robert Dean Dally
Maria Cristina Garcia Paredes
Lawrence Joseph II HEINZ
Jennifer Marie HOWELL
Frank George NJOROGE
Yan Wang
Genshi Zhao
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of PL3759096T3 publication Critical patent/PL3759096T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL19709335T 2018-03-01 2019-02-22 Inhibitory cd73 PL3759096T3 (pl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201862636978P 2018-03-01 2018-03-01
US201862775553P 2018-12-05 2018-12-05
EP19709335.4A EP3759096B1 (en) 2018-03-01 2019-02-22 Cd73 inhibitors
PCT/US2019/019074 WO2019168744A1 (en) 2018-03-01 2019-02-22 Cd73 inhibitors

Publications (1)

Publication Number Publication Date
PL3759096T3 true PL3759096T3 (pl) 2022-05-09

Family

ID=65686120

Family Applications (1)

Application Number Title Priority Date Filing Date
PL19709335T PL3759096T3 (pl) 2018-03-01 2019-02-22 Inhibitory cd73

Country Status (34)

Country Link
US (1) US11028074B2 (pl)
EP (1) EP3759096B1 (pl)
JP (1) JP6794560B2 (pl)
KR (1) KR20200116965A (pl)
CN (1) CN111819173B (pl)
AU (1) AU2019228473B2 (pl)
BR (1) BR112020016066A2 (pl)
CA (1) CA3092661C (pl)
CL (1) CL2020002158A1 (pl)
CO (1) CO2020010191A2 (pl)
CR (1) CR20200376A (pl)
CY (1) CY1125145T1 (pl)
DK (1) DK3759096T3 (pl)
DO (1) DOP2020000148A (pl)
EC (1) ECSP20052897A (pl)
ES (1) ES2909701T3 (pl)
HR (1) HRP20220459T1 (pl)
IL (1) IL277006B2 (pl)
JO (1) JOP20200209A1 (pl)
LT (1) LT3759096T (pl)
MA (1) MA52413A (pl)
MX (1) MX2020009115A (pl)
MY (1) MY200200A (pl)
PE (1) PE20210177A1 (pl)
PH (1) PH12020551464A1 (pl)
PL (1) PL3759096T3 (pl)
PT (1) PT3759096T (pl)
RS (1) RS63073B1 (pl)
SG (1) SG11202008366RA (pl)
SI (1) SI3759096T1 (pl)
TW (1) TWI702954B (pl)
UA (1) UA123890C2 (pl)
WO (1) WO2019168744A1 (pl)
ZA (1) ZA202004805B (pl)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020239048B2 (en) 2019-03-12 2025-10-16 Arcus Biosciences, Inc. Treatment of oncogene-driven cancers
KR20210144821A (ko) 2019-03-29 2021-11-30 아르커스 바이오사이언시즈 인코포레이티드 규명된 아데노신 지문을 이용한 암의 치료방법
AU2020340299B2 (en) * 2019-08-29 2023-10-26 Eli Lilly And Company Crystalline forms of a CD73 inhibitor
WO2021113625A1 (en) * 2019-12-06 2021-06-10 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
TW202206422A (zh) * 2020-04-23 2022-02-16 美商普雷辛肯公司 用於cd73調節之化合物及方法及其適應症
US20240043427A1 (en) * 2020-05-01 2024-02-08 Gilead Sciences, Inc. Cd73 compounds
CN115702150A (zh) * 2020-07-07 2023-02-14 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
CN114057693A (zh) * 2020-08-03 2022-02-18 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
AU2021341258A1 (en) 2020-09-08 2023-04-13 Betta Pharmaceuticals Co., Ltd. CD73 inhibitor and application thereof in medicine
WO2022068929A1 (zh) * 2020-09-30 2022-04-07 武汉人福创新药物研发中心有限公司 嘧啶二酮类化合物及其用途
WO2022090711A1 (en) 2020-10-26 2022-05-05 AdoRx Therapeutics Limited Compounds as cd73 inhibitors
US20230399314A1 (en) * 2020-11-05 2023-12-14 Wuhan Humanwell Innovative Drug Research and Development Center Limited Company Cd73 inhibitor and use thereof
CN114437038B (zh) * 2020-11-05 2025-07-25 武汉人福创新药物研发中心有限公司 哒嗪炔烃类化合物及其用途
WO2022121914A1 (zh) * 2020-12-10 2022-06-16 上海翰森生物医药科技有限公司 氧代氮环类衍生物调节剂、其制备方法和应用
CN114790197A (zh) * 2021-01-25 2022-07-26 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
WO2022195499A1 (en) * 2021-03-19 2022-09-22 Aurigene Discovery Technologies Limited Substituted pyridazine compounds as cd73 inhibitors
PE20241186A1 (es) 2021-10-29 2024-06-03 Gilead Sciences Inc Compuestos de cd73
WO2023169327A1 (zh) * 2022-03-07 2023-09-14 贝达药业股份有限公司 一种哒嗪类衍生物的晶型、制备方法及其应用
AU2023252914A1 (en) 2022-04-13 2024-10-17 Arcus Biosciences, Inc. Combination therapy for treating trop-2 expressing cancers
CA3260083A1 (en) * 2022-07-01 2024-01-04 Gilead Sciences Inc CD73 COMPOUNDS
JP2025524627A (ja) * 2022-07-14 2025-07-30 エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト がんの治療のための複素環化合物
CN117486885A (zh) * 2022-07-26 2024-02-02 中国科学院上海药物研究所 吡唑并嘧啶类化合物的用途
WO2025137640A1 (en) 2023-12-22 2025-06-26 Gilead Sciences, Inc. Azaspiro wrn inhibitors
CN118005615A (zh) * 2024-02-07 2024-05-10 中国药科大学 哒嗪类化合物及其制备方法、药物组合物和应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0709660A2 (pt) 2006-04-03 2011-07-19 Glaxo Group Limided derivados de azabiciclo [3,1,0] hexila como moduladores dos receptores de dopamina d3
EP1860113A1 (en) * 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CA3151595A1 (en) * 2016-01-08 2017-07-13 Arcus Biosciences, Inc. Modulators of 5'-nucleotidase, ecto and the use thereof
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives

Also Published As

Publication number Publication date
TWI702954B (zh) 2020-09-01
ECSP20052897A (es) 2020-09-30
PH12020551464A1 (en) 2021-09-01
JOP20200209A1 (ar) 2020-08-30
IL277006B (en) 2022-11-01
MA52413A (fr) 2021-01-06
UA123890C2 (uk) 2021-06-16
RS63073B1 (sr) 2022-04-29
EP3759096A1 (en) 2021-01-06
HRP20220459T1 (hr) 2022-05-27
AU2019228473B2 (en) 2021-02-25
BR112020016066A2 (pt) 2020-12-08
DOP2020000148A (es) 2020-09-15
ES2909701T3 (es) 2022-05-10
US11028074B2 (en) 2021-06-08
CY1125145T1 (el) 2024-02-16
TW201945002A (zh) 2019-12-01
MX2020009115A (es) 2022-11-15
LT3759096T (lt) 2022-04-11
CN111819173B (zh) 2023-06-06
SI3759096T1 (sl) 2022-07-29
US20210002257A1 (en) 2021-01-07
CR20200376A (es) 2020-10-23
IL277006B2 (en) 2023-03-01
DK3759096T3 (en) 2022-03-07
CL2020002158A1 (es) 2020-11-13
CA3092661C (en) 2022-07-12
MY200200A (en) 2023-12-13
EP3759096B1 (en) 2022-02-16
PE20210177A1 (es) 2021-01-29
SG11202008366RA (en) 2020-09-29
ZA202004805B (en) 2022-01-26
PT3759096T (pt) 2022-03-30
KR20200116965A (ko) 2020-10-13
WO2019168744A1 (en) 2019-09-06
CA3092661A1 (en) 2019-09-06
JP2020517655A (ja) 2020-06-18
CO2020010191A2 (es) 2020-08-31
CN111819173A (zh) 2020-10-23
JP6794560B2 (ja) 2020-12-02
IL277006A (en) 2020-10-29
AU2019228473A1 (en) 2020-08-20

Similar Documents

Publication Publication Date Title
IL277006A (en) CD73 inhibitors
SG11202106520VA (en) Kif18a inhibitors
ZA201905811B (en) Novel inhibitors
EP3843714A4 (en) CD73 INHIBITORS
SG11202010790XA (en) Cd73 inhibitors
SI4051688T1 (sl) Inhibitorji CD73
IL276269A (en) Aminopyrrolotriazines as kinase inhibitors
GB201705971D0 (en) Inhibitor compounds
EP3999517A4 (en) CD73 INHIBITORS
SG11202110534QA (en) Cd73 inhibitors
ZA201907136B (en) Ip6k inhibitors
SG11202102379XA (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
GB201819126D0 (en) Inhibitor compounds
IL276013A (en) pi4kiiibeta inhibitors
IL274550A (en) Dopamine-B-hydroxylase inhibitors
GB2578396B (en) Amidodiamine corrosion inhibitors
GB201819136D0 (en) Inhibitor compounds
GB201721465D0 (en) Inhibitors
HK40057128A (en) Cd73 inhibitors
HK40047148A (zh) Cd73抑制剂
GB201908044D0 (en) Dopamine-B-Hydroxylase inhibitors
GB201905476D0 (en) MAPA4K4 Inhibitors
GB201812462D0 (en) Inhibitors
GB201804439D0 (en) Dopamin-b-hydroxylase inhibitors
GB201809939D0 (en) Eastase inhibitor